Pierre Fabre Launches Pivotal Trial Of Pioneering Prenatal Therapy
XLHED Drug Finally Makes It To The Clinic
Executive Summary
The first boy suffering from X-linked hypohidrotic ectodermal dysplasia has been injected with a protein replacement therapy developed by the French firm and the Esperare Foundation while inside his mother's womb.
You may also be interested in...
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Third Time Lucky For Disabling Skin Disease Biological As EMA Says Yes For PRIME
A biological that is being developed to treat the life-threatening genetic disorder, XLHED, in babies has had its ups and downs, but it has now been accepted on the European Medicines Agency’s PRIME scheme for getting drugs for unmet medical needs to patients faster. Other recipients of PRIME designations this month are Ignyta and, seemingly, GSK.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.